Ruben Mesa, MD from UT Health San Antonio Cancer Center discusses subgroups of patients who benefit from interferon and delaying progression or progression-free survival at the 2017 American Society of Hematology.
Subgroups of Patients who Benefit from Interferon – Delaying progression or progression-free survival
